What are 5-HT7 receptor antagonist drugs?

5-HT7 receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting 5-HT7 receptor). 0 are currently marketed, with 5 more in clinical development.

5-HT7 receptor antagonist

0 marketed 4 in Phase 3 1 in Phase 2

This page covers all 5-HT7 receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting 5-HT7 receptor.

Targets

5-HT7 receptor

Phase 3 pipeline (4)

OPC-34712 · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry/Neurology
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.
NMRA-335140 · Neumora Therapeutics, Inc. · Psychiatry/Neurology
NMRA-335140 is a selective serotonin 5-HT7 receptor antagonist designed to modulate mood and emotional processing through central nervous system effects.
OPC-34712 + ADT · Otsuka Pharmaceutical Development & Commercialization, Inc. · Oncology
OPC-34712 is a selective serotonin 5-HT7 receptor antagonist combined with androgen deprivation therapy (ADT) to treat prostate cancer.
LY2216684 · Eli Lilly and Company · Psychiatry/Neurology
LY2216684 is a selective serotonin 5-HT7 receptor antagonist that modulates serotonergic neurotransmission to treat psychiatric and neurological disorders.

Phase 2 pipeline (1)

DFN-15 Dose 1 · Dr. Reddy's Laboratories Limited · Psychiatry/Neurology
DFN-15 is a selective serotonin 5-HT7 receptor antagonist designed to modulate serotonergic neurotransmission.